Table of Contents
Journal of Signal Transduction
Volume 2010 (2010), Article ID 985132, 7 pages
http://dx.doi.org/10.1155/2010/985132
Review Article

Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells

Jun Sun1,2,3

1Gastroenterology & Hepatology Division, Department of Medicine, University of Rochester, Box 646, 601 Elmwood Avenue, Rochester, NY 14642, USA
2Department of Microbiology and Immunology, University of Rochester, Box 646, 601 Elmwood Avenue, Rochester, NY 14642, USA
3James Wilmot Cancer Center, University of Rochester, Box 646, 601 Elmwood Avenue, Rochester, NY 14642, USA

Received 9 March 2010; Accepted 16 June 2010

Academic Editor: Hiroshi Shibuya

Copyright © 2010 Jun Sun. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Liotta, W. Stetler-Stevenson, and P. S. Steeg, “Metastasis suppressor genes,” Important Advances in Oncology, pp. 85–100, 1991. View at Google Scholar · View at Scopus
  2. L. A. Liotta and W. G. Stetler-Stevenson, “Metalloproteinases and cancer invasion,” Seminars in Cancer Biology, vol. 1, no. 2, pp. 99–106, 1990. View at Google Scholar · View at Scopus
  3. J. S. Rao, “Molecular mechanisms of glioma invasiveness: the role of proteases,” Nature Reviews Cancer, vol. 3, no. 7, pp. 489–501, 2003. View at Google Scholar · View at Scopus
  4. Z. L. Gokaslan, S. K. Chintala, J. E. York et al., “Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors,” Clinical and Experimental Metastasis, vol. 16, no. 8, pp. 721–728, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Kessenbrock, V. Plaks, and Z. Werb, “Matrix metalloproteinases: regulators of the tumor microenvironment,” Cell, vol. 141, no. 1, pp. 52–67, 2010. View at Google Scholar
  6. W. G. Stetler-Stevenson and D.-W. Seo, “TIMP-2: an endogenous inhibitor of angiogenesis,” Trends in Molecular Medicine, vol. 11, no. 3, pp. 97–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. W. G. Stetler-Stevenson, L. A. Liotta, and D. E. Kleiner Jr., “Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis,” FASEB Journal, vol. 7, no. 15, pp. 1434–1441, 1993. View at Google Scholar · View at Scopus
  8. F. Balkwill and L. M. Coussens, “Cancer: an inflammatory link,” Nature, vol. 431, no. 7007, pp. 405–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, no. 11, pp. 798–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, “Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability,” Carcinogenesis, vol. 30, no. 7, pp. 1073–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. R. Greten and M. Karin, “The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer,” Cancer Letters, vol. 206, no. 2, pp. 193–199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Hayden and S. Ghosh, “Signaling to NF-kappaB,” Genes & Development, vol. 18, no. 18, pp. 2195–2224, 2004. View at Google Scholar
  15. M. Karin and F. R. Greten, “NF-κB: linking inflammation and immunity to cancer development and progression,” Nature Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. F. L. Meyskens Jr., J. A. Buckmeier, S. E. McNulty, and N. B. Tohidian, “Activation of nuclear factor-κB in human metastatic melanoma cells and the effect of oxidative stress,” Clinical Cancer Research, vol. 5, no. 5, pp. 1197–1202, 1999. View at Google Scholar · View at Scopus
  17. R. L. Shattuck-Brandt and A. Richmond, “Enhanced degradation of I-κBα contributes to endogenous activation of NF-κB in Hs294T melanoma cells,” Cancer Research, vol. 57, no. 14, pp. 3032–3039, 1997. View at Google Scholar · View at Scopus
  18. K. I. Amiri and A. Richmond, “Role of nuclear factor-κB in melanoma,” Cancer and Metastasis Reviews, vol. 24, no. 2, pp. 301–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Medzhitov, “Origin and physiological roles of inflammation,” Nature, vol. 454, no. 7203, pp. 428–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Nagase and J. F. Woessner Jr., “Matrix metalloproteinases,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999. View at Google Scholar · View at Scopus
  21. C. M. Overall and C. López-Otín, “Strategies for MMP inhibition in cancer: innovations for the post-trial era,” Nature Reviews Cancer, vol. 2, no. 9, pp. 657–672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. W. G. Stetler-Stevenson, “Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities,” Science Signaling, vol. 1, no. 27, p. re6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Valente, G. Fassina, A. Melchiori et al., “TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis,” International Journal of Cancer, vol. 75, no. 2, pp. 246–253, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. W. G. Stetler-Stevenson, H. C. Krutzsch, and L. A. Liotta, “Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family,” Journal of Biological Chemistry, vol. 264, no. 29, pp. 17374–17378, 1989. View at Google Scholar · View at Scopus
  25. W. G. Stetler-Stevenson, “The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 57–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. G. Munshi, Y. I. Wu, S. Mukhopadhyay et al., “Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-β1-induced pericellular collagenolysis,” Journal of Biological Chemistry, vol. 279, no. 37, pp. 39042–39050, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K.-K. Jung, X.-W. Liu, R. Chirco, R. Fridman, and H.-R. C. Kim, “Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein,” EMBO Journal, vol. 25, no. 17, pp. 3934–3942, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. H. Qi, Q. Ebrahem, N. Moore et al., “A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2,” Nature Medicine, vol. 9, no. 4, pp. 407–415, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Yan, S. Zucker, and B. P. Toole, “Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression,” Thrombosis and Haemostasis, vol. 93, no. 2, pp. 199–204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. E. A. Baker, F. G. Bergin, and D. J. Leaper, “Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging,” British Journal of Surgery, vol. 87, no. 9, pp. 1215–1221, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. L. M. Coussens, B. Fingleton, and L. M. Matrisian, “Matrix metalloproteinase inhibitors and cancer: trials and tribulations,” Science, vol. 295, no. 5564, pp. 2387–2392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. S. M. Pulukuri, S. Patibandla, J. Patel, N. Estes, and J. S. Rao, “Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors,” Oncogene, vol. 26, no. 36, pp. 5229–5237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. P. Montgomery, B. M. Mueller, R. A. Reisfeld, S. M. Taylor, and Y. A. DeClerck, “Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line,” Cancer Research, vol. 54, no. 20, pp. 5467–5473, 1994. View at Google Scholar · View at Scopus
  34. R. Khokha, “Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1,” Journal of the National Cancer Institute, vol. 86, no. 4, pp. 299–304, 1994. View at Google Scholar · View at Scopus
  35. O. A. Alvarez, D. F. Carmichael, and Y. A. DeClerck, “Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases,” Journal of the National Cancer Institute, vol. 82, no. 7, pp. 589–595, 1990. View at Google Scholar · View at Scopus
  36. R. Khokha, P. Waterhouse, S. Yagel et al., “Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity of Swiss 3T3 cells,” Science, vol. 243, no. 4893, pp. 947–950, 1989. View at Google Scholar · View at Scopus
  37. T. B. Buck, H. Yoshiji, S. R. Harris, O. R. Bunce, and U. P. Thorgeirsson, “The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice,” Annals of the New York Academy of Sciences, vol. 878, pp. 732–735, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. D. C. Martin, U. Rüther, O. H. Sanchez-Sweatman, F. W. Orr, and R. Khokha, “Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice,” Oncogene, vol. 13, no. 3, pp. 569–576, 1996. View at Google Scholar · View at Scopus
  39. K. M. Finan, G. Hodge, A. M. Reynolds et al., “In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2,” Lung Cancer, vol. 53, no. 3, pp. 273–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. E. A. Baker, T. J. Stephenson, M. W. R. Reed, and N. J. Brown, “Expression of proteinases and inhibitors in human breast cancer progression and survival,” Molecular Pathology, vol. 55, no. 5, pp. 300–304, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. W. C. Parks, C. L. Wilson, and Y. S. López-Boado, “Matrix metalloproteinases as modulators of inflammation and innate immunity,” Nature Reviews Immunology, vol. 4, no. 8, pp. 617–629, 2004. View at Google Scholar · View at Scopus
  43. S. Struyf, P. Proost, J. Vandercappellen et al., “Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects,” European Journal of Immunology, vol. 39, no. 3, pp. 843–857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. E. Kossakowska, D. R. Edwards, C. Prusinkiewicz et al., “Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas,” Blood, vol. 94, no. 6, pp. 2080–2089, 1999. View at Google Scholar · View at Scopus
  45. S. Lacraz, L. Nicod, B. Galve-de Rochemonteix, C. Baumberger, J. M. Dayer, and H. G. Welgus, “Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4,” Journal of Clinical Investigation, vol. 90, no. 2, pp. 382–388, 1992. View at Google Scholar · View at Scopus
  46. S. D. Shapiro, E. J. Campbell, D. K. Kobayashi, and H. G. Welgus, “Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-γ,” Journal of Clinical Investigation, vol. 86, no. 4, pp. 1204–1210, 1990. View at Google Scholar · View at Scopus
  47. S. Lacraz, L. P. Nicod, R. Chicheportiche, H. G. Welgus, and J.-M. Dayer, “IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes,” Journal of Clinical Investigation, vol. 96, no. 5, pp. 2304–2310, 1995. View at Google Scholar · View at Scopus
  48. M. E. Stearns, M. Wang, Y. Hu, F. U. Garcia, and J. Rhim, “Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines,” Clinical Cancer Research, vol. 9, no. 3, pp. 1191–1199, 2003. View at Google Scholar · View at Scopus
  49. I. M. Verma, J. K. Stevenson, E. M. Schwarz, D. Van Antwerp, and S. Miyamoto, “Rel/NF-κB/IκB family: intimate tales of association and dissociation,” Genes and Development, vol. 9, no. 22, pp. 2723–2735, 1995. View at Google Scholar · View at Scopus
  50. G. Bonizzi and M. Karin, “The two NF-κB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Nakanishi and M. Toi, “Nuclear factor-κB inhibitors as sensitizers to anticancer drugs,” Nature Reviews Cancer, vol. 5, no. 4, pp. 297–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Sun and W. G. Stetler-Stevenson, “Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells,” Journal of Molecular Signaling, vol. 4, article 4, 2009. View at Google Scholar
  53. K. Yamashita, M. Suzuki, H. Iwata et al., “Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2),” FEBS Letters, vol. 396, no. 1, pp. 103–107, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. M. L. Corcoran and W. G. Stetler-Stevenson, “Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism,” Journal of Biological Chemistry, vol. 270, no. 22, pp. 13453–13459, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. Nemeth, A. Rafe, M. Steiner, and C. L. Goolsby, “TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin,” Experimental Cell Research, vol. 224, no. 1, pp. 110–115, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Lizárraga, V. Maldonado, and J. Meléndez-Zajgla, “Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 8, pp. 1655–1663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. N. D. Perkins, “NF-κB: tumor promoter or suppressor?” Trends in Cell Biology, vol. 14, no. 2, pp. 64–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan et al., “Stat3 as an oncogene,” Cell, vol. 98, no. 3, pp. 295–303, 1999. View at Google Scholar · View at Scopus
  59. J. E. Harris, M. Fernandez-Vilaseca, P. T. G. Elkington, D. E. Horncastle, M. B. Graeber, and J. S. Friedland, “IFNγ synergizes with IL-1β to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis,” FASEB Journal, vol. 21, no. 2, pp. 356–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Dien, H. M. Amin, N. Chiu et al., “Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer,” American Journal of Pathology, vol. 169, no. 2, pp. 633–642, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Bugno, L. Graeve, P. Gatsios et al., “Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter,” Nucleic Acids Research, vol. 23, no. 24, pp. 5041–5047, 1995. View at Google Scholar · View at Scopus
  62. R. Lai, G. Z. Rassidakis, L. J. Medeiros et al., “Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma,” American Journal of Pathology, vol. 164, no. 6, pp. 2251–2258, 2004. View at Google Scholar · View at Scopus
  63. J. K. Riley, K. Takeda, S. Akira, and R. D. Schreiber, “Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action,” Journal of Biological Chemistry, vol. 274, no. 23, pp. 16513–16521, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. B. E. Bachmeier, C. M. Iancu, M. Jochum, and A. G. Nerlich, “Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach,” Expert Review of Anticancer Therapy, vol. 5, no. 1, pp. 149–163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. B. N. Gomperts and R. M. Strieter, “Chemokine-directed metastasis,” Contributions to Microbiology, vol. 13, pp. 170–190, 2006. View at Google Scholar · View at Scopus
  66. V. B. Andela, A. H. Gordon, G. Zotalis et al., “NFκB: a pivotal transcription factor in prostate cancer metastasis to bone,” Clinical Orthopaedics and Related Research, no. 415, supplement, pp. S75–S85, 2003. View at Google Scholar · View at Scopus